FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031850616> ?p ?o ?g. }

• W2031850616 endingPage "896" @default.
• W2031850616 startingPage "888" @default.
• W2031850616 abstract "Objective To systematically review the literature and to quantitatively evaluate the efficacy and safety of extended pharmacologic treatment of venous thromboembolism (VTE) through network meta-analysis (NMA). Methods A systematic literature search (MEDLINE, Embase, Cochrane CENTRAL, through September 2014) and searching of reference lists of included studies and relevant reviews was conducted to identify randomized controlled trials of patients who completed initial anticoagulant treatment for VTE and then randomized for the extension study; compared extension of anticoagulant treatment to placebo or active control; and reported at least one outcome of interest (VTE or a composite of major bleeding or clinically relevant non-major bleeding). A random-effects Frequentist approach to NMA was used to calculate relative risks with 95% confidence intervals. Results Ten trials (n = 11,079) were included. Risk of bias (assessed with the Cochrane tool) was low in most domains assessed across the included trials. Apixaban (2.5 mg and 5 mg), dabigatran, rivaroxaban, idraparinux and vitamin K antagonists (VKA) each significantly reduced the risk of VTE recurrence compared to placebo, ranging from a 73% reduction with idraparinux to 86% with VKAs. With exception of idraparinux, all active therapies significantly reduced VTE recurrence risk versus aspirin, ranging from a 73% reduction with either apixaban 2.5 mg or rivaroxaban to 80% with VKAs. Apixaban and aspirin were the only therapies that did not increase composite bleeding risk significantly compared to placebo. All active therapies except aspirin increased risk of composite bleeding by 2 to 4-fold compared to apixaban 2.5 mg, with no difference found between the two apixaban doses. Conclusion Extended treatment of VTE is a reasonable approach to provide continued protection from VTE recurrence although bleeding risk is variable across therapeutic options. Our results indicate that apixaban, dabigatran, rivaroxaban, idraparinux and VKAs all reduced VTE recurrence when compared to placebo. Apixaban appears to have a more favorable safety profile compared to other therapies." @default.
• W2031850616 created "2016-06-24" @default.
• W2031850616 creator A5003530505 @default.
• W2031850616 creator A5013056778 @default.
• W2031850616 creator A5024212554 @default.
• W2031850616 creator A5034742104 @default.
• W2031850616 creator A5035518209 @default.
• W2031850616 creator A5068186079 @default.
• W2031850616 date "2015-05-01" @default.
• W2031850616 modified "2023-10-18" @default.
• W2031850616 title "Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis" @default.
• W2031850616 cites W1495967812 @default.
• W2031850616 cites W1974267405 @default.
• W2031850616 cites W1975990989 @default.
• W2031850616 cites W1995777506 @default.
• W2031850616 cites W2007680892 @default.
• W2031850616 cites W2024737544 @default.
• W2031850616 cites W2025593901 @default.
• W2031850616 cites W2098923148 @default.
• W2031850616 cites W2112378432 @default.
• W2031850616 cites W2115787552 @default.
• W2031850616 cites W2125435699 @default.
• W2031850616 cites W2127622911 @default.
• W2031850616 cites W2139785591 @default.
• W2031850616 cites W2143271708 @default.
• W2031850616 cites W2162531249 @default.
• W2031850616 cites W2169472792 @default.
• W2031850616 cites W2170493914 @default.
• W2031850616 cites W2331935930 @default.
• W2031850616 cites W2568332688 @default.
• W2031850616 doi "https://doi.org/10.1016/j.thromres.2015.02.032" @default.
• W2031850616 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25795564" @default.
• W2031850616 hasPublicationYear "2015" @default.
• W2031850616 type Work @default.
• W2031850616 sameAs 2031850616 @default.
• W2031850616 citedByCount "38" @default.
• W2031850616 countsByYear W20318506162015 @default.
• W2031850616 countsByYear W20318506162016 @default.
• W2031850616 countsByYear W20318506162017 @default.
• W2031850616 countsByYear W20318506162019 @default.
• W2031850616 countsByYear W20318506162020 @default.
• W2031850616 countsByYear W20318506162021 @default.
• W2031850616 countsByYear W20318506162022 @default.
• W2031850616 crossrefType "journal-article" @default.
• W2031850616 hasAuthorship W2031850616A5003530505 @default.
• W2031850616 hasAuthorship W2031850616A5013056778 @default.
• W2031850616 hasAuthorship W2031850616A5024212554 @default.
• W2031850616 hasAuthorship W2031850616A5034742104 @default.
• W2031850616 hasAuthorship W2031850616A5035518209 @default.
• W2031850616 hasAuthorship W2031850616A5068186079 @default.
• W2031850616 hasBestOaLocation W20318506162 @default.
• W2031850616 hasConcept C126322002 @default.
• W2031850616 hasConcept C142724271 @default.
• W2031850616 hasConcept C168563851 @default.
• W2031850616 hasConcept C204787440 @default.
• W2031850616 hasConcept C27081682 @default.
• W2031850616 hasConcept C2776301958 @default.
• W2031850616 hasConcept C2777628954 @default.
• W2031850616 hasConcept C2778205648 @default.
• W2031850616 hasConcept C2778661090 @default.
• W2031850616 hasConcept C2778810321 @default.
• W2031850616 hasConcept C2779161974 @default.
• W2031850616 hasConcept C2780638905 @default.
• W2031850616 hasConcept C42219234 @default.
• W2031850616 hasConcept C71924100 @default.
• W2031850616 hasConcept C95190672 @default.
• W2031850616 hasConceptScore W2031850616C126322002 @default.
• W2031850616 hasConceptScore W2031850616C142724271 @default.
• W2031850616 hasConceptScore W2031850616C168563851 @default.
• W2031850616 hasConceptScore W2031850616C204787440 @default.
• W2031850616 hasConceptScore W2031850616C27081682 @default.
• W2031850616 hasConceptScore W2031850616C2776301958 @default.
• W2031850616 hasConceptScore W2031850616C2777628954 @default.
• W2031850616 hasConceptScore W2031850616C2778205648 @default.
• W2031850616 hasConceptScore W2031850616C2778661090 @default.
• W2031850616 hasConceptScore W2031850616C2778810321 @default.
• W2031850616 hasConceptScore W2031850616C2779161974 @default.
• W2031850616 hasConceptScore W2031850616C2780638905 @default.
• W2031850616 hasConceptScore W2031850616C42219234 @default.
• W2031850616 hasConceptScore W2031850616C71924100 @default.
• W2031850616 hasConceptScore W2031850616C95190672 @default.
• W2031850616 hasIssue "5" @default.
• W2031850616 hasLocation W20318506161 @default.
• W2031850616 hasLocation W20318506162 @default.
• W2031850616 hasLocation W20318506163 @default.
• W2031850616 hasLocation W20318506164 @default.
• W2031850616 hasOpenAccess W2031850616 @default.
• W2031850616 hasPrimaryLocation W20318506161 @default.
• W2031850616 hasRelatedWork W1980555552 @default.
• W2031850616 hasRelatedWork W1980640915 @default.
• W2031850616 hasRelatedWork W1996418069 @default.
• W2031850616 hasRelatedWork W2065357039 @default.
• W2031850616 hasRelatedWork W2131854220 @default.
• W2031850616 hasRelatedWork W2167924766 @default.
• W2031850616 hasRelatedWork W2344877074 @default.
• W2031850616 hasRelatedWork W2576538605 @default.
• W2031850616 hasRelatedWork W2741829680 @default.
• W2031850616 hasRelatedWork W2908436399 @default.

• next